✨ Free AI Report
Sanofi S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Sanofi S.A.
Company Research

Sanofi S.A.: Business Overview, Financials & Competitive Analysis

Sanofi S.A. scores 8/10 on the AskCyborg Cyborg Score (Strong). Sanofi is a well-positioned global pharma leader with strong 2025 momentum, innovative pipeline delivery, and AI-driven transformation driving margin expansion. Sanofi reported 9.9% sales growth for 2025, reaching EUR 43.6 billion, and delivered 13.3% sales growth in Q4. The company expects sales to grow by a high single-digit percentage in.

What is Sanofi S.A.'s industry? Sanofi S.A. (sanofi.com) operates in Biopharmaceuticals - Pharmaceuticals & Vaccines. AskCyborg classifies Sanofi S.A. under Biopharmaceuticals - Pharmaceuticals & Vaccines in its company registry.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The company discovers, develops, manufactures, and markets an array of medicines and vaccines, with its portfolio inc...

8/ 10Strong

Cyborg Score thesis

Sanofi is a well-positioned global pharma leader with strong 2025 momentum, innovative pipeline delivery, and AI-driven...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Pharmaceuticals & Vaccines
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Sanofi S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Sanofi S.A.

AskCyborg analysts argue the bull and bear cases for Sanofi S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Sanofi S.A. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Sanofi S.A. Overview

Pro stress-test →

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The company discovers, develops, manufactures, and markets an array of medicines and vaccines, with its portfolio including medicines for cancer, rare diseases, and multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products.

Strategic Profile

Pro stress-test →

In 2025, sales increased by 9.9% at constant exchange rates, while business EPS improved significantly faster by 15.0%. The company leverages AI-driven supply chain management that enabled it to avoid $300 million in revenue risk, and combining machine learning with lab research has helped discover 10 completely new drug targets in just one year.

Competitive Landscape

Pro stress-test →

Top competitors include Merck, AbbVie, and Amgen. Sanofi competes in highly competitive specialty pharma and vaccine markets with other diversified players like Johnson & Johnson, Roche, and Novartis, differentiating through its large portfolio breadth, emerging vaccine franchise, and rare disease expertise.

Industry Context

Sanofi S.A. operates in Biopharmaceuticals - Pharmaceuticals & Vaccines.

Key facts

Founded: 1973 · Headquarters: Paris, France · Revenue: EUR 43.6B (2025)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Sanofi S.A..

  • Dupixent achieved EUR 15.7 billion in sales with over 30% patient growth, while three new medicines and vaccines (Qfitlia, Wayrilz, Nuvaxovid) were launched in 2025 and ALTUVIIIO and Beyfortus achieved blockbuster status.
  • The company delivered 12 Phase III and 15 Phase II readouts, 20 regulatory approvals, and multiple late-stage programs advancing in 2025.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Strategic investment of up to $25 million in Adagene for masked antibody therapy collaboration
  • December 2025Acquired Dynavax to add hepatitis B vaccine and shingles candidate to portfolio
  • +2 moreTrack every material event for Sanofi S.A. as it happens. Explore monitoring →
Get alerted when Sanofi S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DupixentLeading biologic for atopic dermatitis and other inflammatory conditions→KeytrudaLeading oncology immunotherapy→RinvoqJAK inhibitor for inflammatory conditions→OtezlaSmall molecule immunology therapy→

Compare Sanofi S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Sanofi S.A. operates in Biopharmaceuticals - Pharmaceuticals & Vaccines. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Pharmaceuticals & Vaccines research →
NEW · MCP server

Ask your AI assistant about Sanofi S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Sanofi S.A. and its top competitor on Cyborg Score”
“What did Sanofi S.A. do this quarter?”
“Is Sanofi S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Sanofi S.A. do?+
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The company discovers, develops, manufactures, and markets an array of medicines and vaccines, with its portfolio inc...
What is Sanofi S.A.'s Cyborg Score?+
Sanofi S.A. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Sanofi S.A.'s main competitors?+
Named competitors include Dupixent, Keytruda, Rinvoq, Otezla. The full competitive landscape is in the AskCyborg report.
How can I get the full Sanofi S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Sanofi S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Sanofi S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Pharmaceuticals & Vaccines research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Sanofi S.A.